Intended Use Study of the BD SurePath Plus™ Pap
Sponsor: Becton, Dickinson and Company
Terminated
Decided not to pursue commercialization of the product
Other terminated trials from Becton, Dickinson and Company
Other Neoplasms trials with similar outcome
A observational or N/A phase clinical study on Neoplasms and Neoplasms by Histologic Type, this trial is terminated or withdrawn. The trial is conducted by Becton, Dickinson and Company and has accumulated 10 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Jun 2023 — Jul 2024 [monthly]
Terminated
-
Oct 2021 — Jun 2023 [monthly]
Terminated
Status: Withheld → Terminated
-
Jun 2021 — Oct 2021 [monthly]
Withheld
▶ Show 5 earlier versions
-
Jan 2021 — Jun 2021 [monthly]
Withheld
-
Jun 2018 — Jan 2021 [monthly]
Withheld
-
Apr 2018 — Jun 2018 [monthly]
Withheld
Phase: NA → None
-
Feb 2017 — Apr 2018 [monthly]
Withheld NA
-
Jan 2017 — Feb 2017 [monthly]
Withheld NA
First recorded
Sep 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Becton, Dickinson and Company
For direct contact, visit the study record on ClinicalTrials.gov .